For research use only. Not for therapeutic Use.
Bromperidol (Cat.No:I000253), also known as Bromperidol decanoate, is a butyrophenone derivative and a highly potent antipsychotic drug. It acts as a dopamine receptor antagonist, primarily at the D2 receptor, and is used for the treatment of schizophrenia and other psychotic disorders. It has a long-acting form, decanoate, which is administered via intramuscular injection. Side effects may include extrapyramidal symptoms, tardive dyskinesia, and neuroleptic malignant syndrome.
| Catalog Number | I000253 |
| CAS Number | 10457-90-6 |
| Molecular Formula | C21H23BrFNO2 |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | DMSO: 34 mg/mL |
| Storage | Store at -20℃ |
| IUPAC Name | 4-[4-(4-bromophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one |
| InChI | InChI=1S/C21H23BrFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2 |
| InChIKey | RKLNONIVDFXQRX-UHFFFAOYSA-N |
| SMILES | O=C(C1=CC=C(F)C=C1)CCCN2CCC(O)(C3=CC=C(Br)C=C3)CC2 |
| Reference | </br>1:Comparison of the anti-dopamine D₂ and anti-serotonin 5-HT(2A) activities of chlorpromazine, bromperidol, haloperidol and second-generation antipsychotics parent compounds and metabolites thereof. Suzuki H, Gen K, Inoue Y.J Psychopharmacol. 2013 Apr;27(4):396-400. doi: 10.1177/0269881113478281. Epub 2013 Feb 20. PMID: 23427194 </br>2:Bromperidol decanoate (depot) for schizophrenia. Purgato M, Adams CE.Cochrane Database Syst Rev. 2012 Nov 14;11:CD001719. doi: 10.1002/14651858.CD001719.pub4. Review. PMID: 23152208 </br>3:Bromperidol decanoate (depot) for schizophrenia. Purgato M, Adams CE.Cochrane Database Syst Rev. 2011 Sep 7;(9):CD001719. doi: 10.1002/14651858.CD001719.pub3. Review. Update in: Cochrane Database Syst Rev. 2012;11:CD001719. PMID: 21901678 </br>4:Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia. Gopal S, Berwaerts J, Nuamah I, Akhras K, Coppola D, Daly E, Hough D, Palumbo J.Neuropsychiatr Dis Treat. 2011;7:93-101. doi: 10.2147/NDT.S17177. Epub 2011 Mar 8. PMID: 21552311 Free PMC Article</br>5:Sensitive determination of 4-(4-bromophenyl)-4-hydroxypiperidine, a metabolite of bromperidol, in rat plasma by HPLC with fluorescence detection after pre-column derivatization using 4-fluoro-7-nitro-2,1,3-benzoxadiazole. Higashi Y, Nakamura S, Fujii Y.Biol Pharm Bull. 2006 Dec;29(12):2479-82. PMID: 17142985 Free Article</br>6:Pharmacokinetic parameters of bromperidol in Korean subjects. Lee SY, Kim YG, Kim HG, Kim JW.Hum Psychopharmacol. 2006 Aug;21(6):409-12. PMID: 16915578 </br>7:Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Yasui-Furukori N, Saito M, Nakagami T, Kaneda A, Tateishi T, Kaneko S.Prog Neuropsychopharmacol Biol Psychiatry. 2006 Mar;30(2):286-91. Epub 2006 Jan 4. PMID: 16386826 </br>8:Depot bromperidol decanoate for schizophrenia. Wong D, Adams CE, David A, Quraishi SN.Cochrane Database Syst Rev. 2004;(3):CD001719. Review. Update in: Cochrane Database Syst Rev. 2011;(9):CD001719. PMID: 15266450 </br>9:Establishment of new cloned enzyme donor immunoassays (CEDIA) for haloperidol and bromperidol. Yasui-Furukori N, Saito M, Furukori H, Inoue Y, Someya T, Kaneko S, Tateishi T.Ther Drug Monit. 2004 Jun;26(3):336-41. PMID: 15167638 </br>10:Simultaneous determination of haloperidol and bromperidol and their reduced metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography. Yasui-Furukori N, Inoue Y, Chiba M, Tateishi T.J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Jun 5;805(1):175-80. PMID: 15113555 |
